Markets:

Overview

News

Currencies

International

Treasuries

Anavex Life Sciences Corp. - Common Stock (NQ:AVXL)

3.450 +0.370 (+12.01%)

Streaming Delayed Price Updated: 2:29 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

NASDAQ:AVXL Shareholder Notice: Investigation over Potential Securities Laws Violations by Anavex Life Sciences Corp. ↗

February 23, 2022

San Diego, CA -- (SBWIRE) -- 02/23/2022 -- Anavex Life Sciences Corp. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗

February 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: Anavex Life Sciences Q1 Earnings ↗

February 09, 2022

Anavex Life Sciences (NASDAQ:AVXL) reported its Q1 earnings results on Wednesday, February 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 9, 2022 ↗

February 09, 2022

Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion.

Via Benzinga

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm

February 04, 2022

Los Angeles - (NewMediaWire) - February 04, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life...

Via NewMediaWire

Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals ↗

February 01, 2022

Anavex Life Sciences Corp (NASDAQ: AVXL) reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome.

Via Benzinga

Investigation Notice: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm

February 03, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

ANAVEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Anavex Life Sciences Corp. on Behalf of Anavex Stockholders and Encourages Investors to Contact the Firm

February 02, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors

February 02, 2022

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors

February 02, 2022

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Anavex Life Sciences Corp. (AVXL) on Behalf of Investors

February 02, 2022

From The Law Offices of Frank R. Cruz

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $100,000 to Contact the Firm

February 02, 2022

From The Schall Law Firm

Via Business Wire

23 Stocks Moving in Wednesday's Pre-Market Session ↗

February 02, 2022

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Also check out: Executives buy more than $600 million of 3...

Via Benzinga

52 Biggest Movers From Yesterday ↗

February 02, 2022

Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969. Synaptogenix, Inc. (NASDAQ: SNPX) climbed 29.4% to close at $10.09. Synaptogenix...

Via Benzinga

Mid-Afternoon Market Update: Dow Rises 50 Points; DLH Holdings Shares Drop ↗

February 01, 2022

US stocks traded mixed in the afternoon session on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses.

Via Benzinga

Anavex Life Sciences Crashes As Last-Minute Testing Edits Cloud Drug's Impact ↗

February 01, 2022

Just two weeks ago, Anavex edited the goals of its study in Rett syndrome.

Via Investor's Business Daily

34 Stocks Moving In Tuesday's Mid-Day Session ↗

February 01, 2022

Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 01, 2022

Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K...

Via Benzinga

Mid-Day Market Update: Pitney Bowes Drops After Q4 Earnings; Biofrontera Shares Climb ↗

February 01, 2022

US stocks traded mostly flat on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses.

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower Following Monday's Rally; UPS Earnings Top Views ↗

February 01, 2022

US stocks started the first trading day of new month on a cautious note after recording gains on Monday. Wall Street closed the volatile January month with steep losses.

Via Benzinga

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗

February 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 14, 2022

Gainers Molecular Partners (NASDAQ:MOLN) shares moved upwards by 11.9% to $31.66 during Friday's pre-market session. The market value of their outstanding shares is at...

Via Benzinga

Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study ↗

January 10, 2022

Anavex Life Sciences Corp (NASDAQ: AVXL) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including...

Via Benzinga

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key...

Via Talk Markets

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 24, 2021

Gainers iSpecimen (NASDAQ:ISPC) shares in...

Via Benzinga

The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗

November 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...

Via Benzinga

Topics Intellectual Property

Earnings Scheduled For November 24, 2021 ↗

November 24, 2021

Companies Reporting Before The Bell • Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on revenue of $31.75 million. • Anavex Life...

Via Benzinga

Earnings Outlook For Anavex Life Sciences ↗

November 23, 2021

Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement....

Via Benzinga

The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.